First human test: how a new liver drug behaves in sick and healthy people
NCT ID NCT05917938
Summary
This early study tested a new drug being developed for fatty liver disease. Researchers gave a single injection to 33 people, some with liver problems and some with healthy livers, to see how their bodies processed the drug and to check for side effects. The main goal was to understand if the drug is safe and how it behaves differently in people with various levels of liver function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
APEX Research
München, 81241, Germany
-
Cardiomedicum Sp. z o.o.
Krakow, 30-002, Poland
-
Summit Clinical Research s.r.o.
Bratislava, 83101, Slovakia
-
Summit Clinical Research s.r.o.
Malacky, 901 22, Slovakia
-
Uniwersyteckie Centrum Kliniczne (UCK)
Gdansk, 80-214, Poland
Conditions
Explore the condition pages connected to this study.